Astrocytoma Market Report gives readers a thorough assessment of key market drivers, restraints, prospects, opportunities, restraints, current trends, and technological and industrial breakthroughs that will influence market growth. The detailed market research, industry sector growth and development, and new product introductions covered in this report on the Astrocytoma Market are of great assistance to the important new commercial players joining the market.
This Astrocytoma Market report research conducts a careful market evaluation and provides a professional analysis of the industry taking into account market development, present market circumstances, and forecasts for the future. The market driving factors, market overview, industry volume, and market share are also highlighted in this Astrocytoma Market report analysis.
Regions Covered in the Report-
Click the link to get a Sample Copy of the Report before purchase-https://www.delveinsight.com/sample-request/astrocytoma-market
Astrocytoma: An Overview
Astrocytoma is generally categorized into grades as, Pilocytic Astrocytoma, Pleomorphic Xantoastrocytoma and Sub ependymal Giant Cell Astrocytoma (SEGA) in Grade 1, Diffuse Astrocytoma in Grade 2, Anaplastic Astrocytoma in Grade 3, and Glioblastoma (GBM) in Grade 4.
Key highlights of the Astrocytoma Market Report
Astrocytoma Epidemiology Insights
Pilocytic astrocytoma (PA) accounts for only 2% of all CNS neoplasms and 6% of all gliomas.3 the annual incidence rate is roughly 0.3 per 100,000 person-years. In children, PA is the most common form of glioma, with a median age of diagnosis being 13 years. Although most frequent in children, it may also be seen in adults of virtually any age, even into the 60s and 70s.
Astrocytoma Epidemiology Segmentation in the 7MM
Astrocytoma Treatment Market
Available adjuvant therapies
Steroids: Dexamethasone is used to relieve symptoms due to the brain swelling that is often associated to the tumor. Unfortunately, it does not have any action against the tumor, and it is associated to significant side effects when used for periods longer than 2-3 weeks.
Chemotherapy: Temozolomide (TMZ), developed by Merck (trade name Temodar) works by slightly modifying the DNA of tumor cells. This triggers its breakage and consequent death of the cell, unless DNA repair mechanisms override the damage. TMZ is a common first line treatment for grade 3 or 4 astrocytoma and may also occasionally be used for grade 2.
Radiotherapy: Radiation has been at the basis of treatment of astrocytomas for the past 50 years and it is extremely effective, at least for the first few months after treatment. Radiation, too, works by damaging DNA of the tumor cells, thus inducing their death. Under standard protocols, the treatment consists of small doses of radiation in the area of the tumor.
Bevacizumab (Avastin): Bevacizumab blocks the tumor’s ability to recruit blood vessels so that they can feed themselves and keep growing. Avastin has been approved by the US FDA in 2013 for its use in recurrent glioblastomas. It is very effective in reducing the swelling associated with the tumor and often helps improving symptoms.
Astrocytoma Market Insights
The brain is made up of various types of cells, including neurons, which constitute the electric circuitry responsible for brain functions, and astrocytes, which provide the structure and support for neurons to work properly. Astrocytoma is a type of cancer that can form in the brain or spinal cord. It begins in cells called astrocytes that support nerve cells, and are the most common brain tumors in adult individuals.
Astrocytoma Market Forecast
Some genetic conditions increase the chance of developing brain tumors, for example, neurofibromatosis type 1 (NF1). This genetic condition causes tumors to grow along the nerves and in the brain. Around 10% of people who have NF1 are diagnosed with Pilocytic Astrocytoma.
Astrocytoma Market Size
The market size shall grow during the forecast period, i.e., 2022–2032 owing to the increasing incidence of brain tumors. The market size is expected to increase during the study period.
Astrocytoma Market Dynamics
The dynamics of Astrocytoma market is anticipated to change in the coming years owing to the improvement in the diagnosis technologies, incremental healthcare spending across the world, increasing incidence and emerging novel therapies during the forecast period of 2022-2032. Key players such as Denovo Biopharma, Orbus Therapeutics, Onconeutics, Celgene, Oblato and various others are involved in developing therapies for Astrocytoma.
Make an Enquiry Before Buying- https://www.delveinsight.com/sample-request/astrocytoma-market
Table of Content
Astrocytoma Market Report Highlights
Why should you buy this report?
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/